CLINICAL_TRIALS
ClinicalTrials.gov record update
Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in Type 2 Diabetes Mellitus (T2DM)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05093517
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:26:17.657299+00:00
- Published At
- 2024-08-09T00:00:00+00:00
- Record Updated At
- 2024-08-09
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Type 2 Diabetes", "Glucose Tolerance Impaired", "Insulin Sensitivity"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2024-08-09"- protocolSection.identificationModule.nctId
"NCT05093517"- protocolSection.identificationModule.officialTitle
"Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in Type 2 Diabetes Mellitus (T2DM)"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["EARLY_PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.